REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Renal osteodystrophy is a spectrum of skeletal disorders ranging from high-turnover lesions of secondary hyperparathyroidism (2HPT), in which serum parathyroid homornes (PTH) levels are substantially elevated, to low-turnover lesions such as adynamic bone, in which serum PTH levels are normal or minimally increased. In children with end-stage renal disease (ESRD), 2HPT remains the most common disorder, and treatment with calcitriol is often required. Large twice-weekly doses of calcitriol are commonly used to reduce serum PHT levels and lower bone formation and turnover in those patients with 2HPT, but adynamic renal osteodystrophy can develop after only eight to 12 months of treatment.